Raised risk of Wilms tumour in patients with aniridia and submicroscopic WT1 deletion

Journal of Medical Genetics

Volumn 44, Issue 12, 2007, Pages 787-790

  Van Heyningen, Veronica ^a   Hoovers, Jan M N ^b   De Kraker, Jan ^c   Crolla, John A ^d  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d SALISBURY DISTRICT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WT1 PROTEIN;

ADOLESCENT; ADULT; ANIRIDIA; ARTICLE; CANCER RISK; CHROMOSOME 11P; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE MUTATION; HUMAN; MALE; NEPHROBLASTOMA; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGE OF ONSET; ANIRIDIA; CHILD; CHILD, PRESCHOOL; CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN, PAIR 11; EYE PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; GENES, WILMS TUMOR; GENETIC PREDISPOSITION TO DISEASE; HOMEODOMAIN PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KIDNEY NEOPLASMS; MALE; MICROSCOPY; PAIRED BOX TRANSCRIPTION FACTORS; REPRESSOR PROTEINS; WILMS TUMOR;

EID: 37249029131     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2007.051318     Document Type: Article

References (25)

1. Prosser J, van Heyningen V. PAX6 mutations reviewed. Hum Mutat 1998;11:93-108.
2. Crolla JA, van Heyningen V. Frequent chromosome aberrations revealed by molecular cytogenetic studies in patients with aniridia. Am J Hum Genet 2002;71:1138-49.
3. Nelson LB, Spaeth GL, Nowinski TS, Margo CE, Jackson L. Aniridia. A review. Surv Ophthalmol 1984;28:621-42.
4. Sisodiya SM, Free SL, Williamson KA, Mitchell TN, Willis C, Stevens JM, Kendall BE, Shorvon SD, Hanson IM, Moore AT, van Heyningen V. PAX6 haploinsufficiency causes cerebral malformation and olfactory dysfunction in humans. Nat Genet 2001;28:214-16.
5. van Heyningen V, Williamson KA. PAX6 in sensory development. Hum Mol Genet 2002;11:1161-7.
6. Gronskov K, Olsen JH, Sand A, Pedersen W, Carlsen N, Bak Jylling AM, Lyngbye T, Brondum-Nielsen K, Rosenberg T. Population-based risk estimates of Wilms tumor in sporadic aniridia. A comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia. Hum Genet 2001;109:11-18.
7. Breslow NE, Norris R, Norkool PA, Kang T, Beckwith JB, Perlman EJ, Ritchey ML, Green DM, Nichols KE. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group. J Clin Oncol 2003;21:4579-85.
8. Dome JS, Coppes MJ. Recent advances in Wilms tumor genetics. Curr Opin Pediatr 2002;14:5-11.
9. Royer-Pokora B, Beier M, Henzler M, Alam R, Schumacher V, Weirich A, Huff V. Twenty-four new cases of WT1 germline mutations and review of the literature: genotype/phenotype correlations for Wilms tumor development. Am J Med Genet A 2004;127:249-57.
10. Breslow NE, Collins AJ, Ritchey ML, Grigoriev YA, Peterson SM, Green DM. End stage renal disease in patients with Wilms tumor: results from the National Wilms Tumor Study Group and the United States Renal Data System. J Urol 2005;174:1972-5.
11. Mannens M, Hoovers JM, Bleeker-Wagemakers EM, Redeker E, Bliek J, Overbeeke-Melkert M, Saunders G, Williams B, van Heyningen V, Junien C, Haber D, Speleman F, Heyting C, Slater RM, Leschort NJ, Westerveld A. The distal region of 11p13 and associated genetic diseases. Genomics 1991;11:284-93.
12. Fantes JA, Bickmore WA, Fletcher JM, Ballesta F, Hanson IM, van Heyningen V. Submicroscopic deletions at the WAGR locus, revealed by nonradioactive in situ hybridization. Am J Hum Genet 1992;51:1286- 94.
13. Crolla JA, Cawdery JE, Oley CA, Young ID, Gray J, Fantes J, van Heyningen V. A FISH approach to defining the extent and possible clinical significance of deletions at the WAGR locus. J Med Genet 1997;34:207-12.
14. Fantes JA, Oghene K, Boyle S, Danes S, Fletcher JM, Bruford EA, Williamson K, Seawright A, Schedl A, Hanson I, Zehetner G, Bhogal R, Lehrach H, Gregory S, Williams J, Little PFR, Sellar GC, Hoovers J, Mannens M, Weissenbach J, Junien C, van Heyningen V. A high-resolution integrated physical, cytogenetic, and genetic map of human chromosome 11: distal p13 to proximal p15.1. Genomics 1995;25:447-61.
15. van Heyningen V, Little PF. Report of the fourth international workshop on human chromosome U mapping 1994. Cytogenet Cell Genet 1995;69:127-58.
16. Henry I, Hoovers J, Barichard F, Bertheas MF, Puech A, Prieur F, Gessler M, Bruns G, Mannens M, Junien C. Pericentric intrachromosomal insertion responsible for recurrence of del(11)(p13p14) in a family. Genes Chromosomes Cancer 1993;7:57-62.
17. Kent J, Lee M, Schedl A, Boyle S, Fantes J, Powell M, Rushmere N, Abbott C, van Heyningen V, Bickmore WA. The reticulocalbin gene maps to the WAGR region in human and to the Small eye Harwell deletion in mouse. Genomics 1997;42:260-7.
18. Drechsler M, Meijers-Heijboer FJ, Schneider S, Schurich B, Grond-Ginsbach C, Tariverdian G, Kantner G, Blankenagel A, Kaps D, Schroeder-Kurth T, Royer-Pokora B. Molecular analysis of aniridia patients for deletions involving the Wilms' tumor gene. Hum Genet 1994;94:331- 8.
19. Dao DD, Schroeder WT, Chao LY, Kikuchi H, Strong LC, Riccardi VM, Pathak S, Nichols WW, Lewis WH, Saunders GF. Genetic mechanisms of tumor-specific loss of 11p DNA sequences in Wilms tumor. Am J Hum Genet 1987;41:202-17.
20. Gessler M, Konig A, Moore J, Qualman S, Arden K, Cavenee W, Bruns G. Homozygous inactivation of WT1 in a Wilms' tumor associated with the WAGR syndrome. Genes Chromosomes Cancer 1993;7:131-6.
21. Albrecht P, Ansperger-Rescher B, Schuler A, Zeschnigk M, Gallie B, Lohmann DR. Spectrum of gross deletions and insertions in the RB1 gene in patients with retinoblastoma and association with phenotypic expression. Hum Mutat 2005;26:437-45.
22. Thienpont B, Vermeesch JR, Fryns JP. 25 Mb deletion of 13q13.3→q21.31 in a patient without retinoblastoma. Eur J Med Genet 2005;48:363-6.
23. Niaudet P, Gubler MC. WT1 and glomerular diseases. Pediatr Nephrol 2006;21:1653-60.
24. Moore AW, McInnes L, Kreidberg J, Hastie ND, Schedl A. YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development 1999;126:1845-57.
25. Guo JK, Menke AL, Gubler MC, Clarke AR, Harrison D, Hammes A, Hastie ND, Schedl A. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet 2002;11:651-9.